Tune Therapeutics
Dr. Ali Behbahani is a Board Member at Tune Therapeutics and a General Partner at New Enterprise Associates (NEA).
He specializes in investments in the biopharmaceutical and medical device sectors. Prior to NEA, he served as a business development consultant at The Medicines Company, as a Venture Associate with Morgan Stanley Venture Partners, and as a Healthcare Investment Banking Analyst with Lehman Brothers. He has been a Board Member at Nevro Corp., and a Member of the Board of Directors at Genocea Biosciences, Oyster Point Pharma, Adaptimmune, Black Diamond, and CRISPR Therapeutics.
Ali received his bachelor’s degrees in Biomedical Engineering, Electrical Engineering, and Chemistry from Duke University; his M.B.A. from the Wharton School of the University of Pennsylvania; and his M.D. from the University of Pennsylvania School of Medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.